Vietnam to carry out clinical trials of France’s XAV-19 Covid-19 drug
XAV-19 is a coronavirus treatment drug based on polyclonal antibodies that targets Covis-19 patients with moderate conditions.
Vietnam is ready to go on with the third phase of clinical trials of France’s XAV-19 Covid-19 drug and seeks the transfer of its production technology, Deputy Minister of Health (MoH) Tran Van Thuan said at an online working session with Xenothera Company, the drug maker, on September 7.
The session saw the attendance of leaders and experts from the MoH, as well as President Odile Duvaux and CEO Bernard Vanhove of Xenothera Company.
Odile Duvaux said that Xenothera Company is willing to cooperate with Vietnam in implementing the third phase of the trials and to engage in further discussions on the transfer of the drug production technology to Vietnam.
Medical staff gives Covid-19 treatment to patients. Photo: Ngoc Duong
For his part, Deputy Minister Tran Van Thuan highly valued the encouraging results that XAV-19 has achieved in both the first and second phases of the clinical trial.
The deputy minister affirmed Vietnam’s willingness to cooperate with Xenothera in implementing the third phase clinical trials of XAV-19 and receiving technology transfer for production of the drug from the firm.
In May 2021, the MoH and Solidarity of France ordered 30,000 doses of XAV-19 from Xenothera.
According to the Ministry of Health, XAV-19 is a coronavirus treatment drug based on polyclonal antibodies that target Covis-19 patients with moderate conditions.
The latest technology XAV-19 represents a polyclonal antibody directed against the SARS-CoV-2 which has been researched and developed by Nantes-based biotech Xenothera.
The results of the first and second phases of XAV-19 clinical trials showed that the drug is effective and safe in preventing the virus progression, neutralizing the virus, and reducing inflammation in patients.
The third phase of clinical trials of XAV-19 is getting underway in France, along with other European countries such as Greece, Bulgaria, Romania, and Spain.
XAV-19 has so far proved to be effective against various SARS-CoV-2 strains, with this polyclonal antibody also having the ability to create immediate immunity and prevent viruses from entering cells.
This represents an important difference from the monoclonal antibodies which are used to treat patients in the early stages of infection.
- Australia, Vietnam launch US$37M human resource program for 2021-2025
- Vietnam’s biggest Covid-19 makeshift hospital to be closed
- Vietnam to contribute US$5 million medical supplies to ASEAN
- Hanoi hospital lockdown ends
- Vietnam starts Covid-19 vaccine administration for children aged 12-17
- Vietnam strives to fully vaccinate 95% of adolescents against Covid-19
- Vaccines and treatment drugs - key solutions to fight Covid-19 in Vietnam
- Vietnam receives 740,000 Russian-made vaccine doses
- Vietnam successfully produces first batch of Russian Covid-19 vaccine
- Covid home treatment - a solution for Vietnam to safely live with Covid-19: UK experts
Raising public awareness remains key to lifting EC’s yellow card: Experts
Hanoians enjoy fresh air and sunlight at the weekend
Vietnam’s trade turnover projected to reach record high of US$600 billion in 2021
Mao Bookstore - the oldest bookstore in Dinh Le Street
Vietnam’s biggest Covid-19 makeshift hospital to be closed
UN Security Council holds emergency meeting over North Korea
“Banana” millionaires along Hanoi’s Red River
Vietnamese army required to intensify peacekeeping missions
Vietnam GDP growth predicted to hit 1.8% in 2021: VESS